Evidence map›Paper›PMID 39770761›Full record

ArticleMicroorganisms2024

Viral Metagenomics in Patients Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): A Brazilian Experience.

Gabriel Montenegro de Campos, Thalita Cristina de Mello Costa, Roberta Maraninchi Silveira, Ian Nunes Valença, Rafael Dos Santos Bezerra, Luiz Guilherme Darrigo Junior, Ana Carolina de Jesus Vieira, Camila Campos Mesquita, Patrícia da Silva Laurindo, Renato Guerino Cunha and 7 more

Abstract read
In one paragraph

Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Gabriel Montenegro de CamposBlood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 05508-220, SP, Brazil.ORCID 0000-0001-5181-415X
Thalita Cristina de Mello CostaDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Roberta Maraninchi SilveiraBlood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 05508-220, SP, Brazil.
Ian Nunes ValençaBlood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 05508-220, SP, Brazil.ORCID 0000-0001-6614-2755
Rafael Dos Santos BezerraBlood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 05508-220, SP, Brazil.
Luiz Guilherme Darrigo JuniorDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.ORCID 0000-0001-6007-8908
Ana Carolina de Jesus VieiraDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Camila Campos MesquitaDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Patrícia da Silva LaurindoDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Renato Guerino CunhaCellular Thearpy Program, Oncolcínicas, São Paulo 13571-410, SP, Brazil.ORCID 0000-0003-3936-0129
Simone KashimaBlood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 05508-220, SP, Brazil.
Dimas Tadeu CovasDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Belinda Pinto SimõesDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14040-900, SP, Brazil.
Sandra Coccuzzo SampaioCenter for Viral Surveillance and Serological Evaluation (CeVIVAs), Butantan Institute, São Paulo 05585-000, SP, Brazil.
Maria Carolina EliasCenter for Viral Surveillance and Serological Evaluation (CeVIVAs), Butantan Institute, São Paulo 05585-000, SP, Brazil.ORCID 0000-0002-0501-8280
Marta GiovanettiDepartment of Sciences and Technologies for Sustainable Development and One Health, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.ORCID 0000-0002-5849-7326
Svetoslav Nanev SlavovCenter for Viral Surveillance and Serological Evaluation (CeVIVAs), Butantan Institute, São Paulo 05585-000, SP, Brazil.ORCID 0000-0003-0805-6140

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/23205-8; 2021/11944-6; 2023/12155-0; 2019/08528-0; 2019/07861-8
6 · The paper itself

Abstract

Viral infections are one of the most important causes of morbidity and mortality among patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Immunosuppression may lead to the reactivation of latent viruses or the acquisition of new infections, resulting in severe clinical outcomes. The early detection of viral reactivations is crucial for effective patient management and post-transplant care. In this study, we employed next-generation metagenomics to assess changes in viral abundance and detect clinically significant viruses in allogeneic HSCT patients. A total of 20 patients from the Transplant Unit of the University Hospital of the Faculty of Medicine of Ribeirão Preto, University of São Paulo were included, with plasma samples collected at three time points: D + 0 (pre-transplantation), D + 30 (30 days post-transplantation), and D + 100 (~100 days post-transplantation). A higher presence of clinically relevant viruses, such as the cytomegalovirus (CMV), the Epstein-Barr virus (EBV) and adenoviruses, were predominantly detected at D + 30. The diversity of commensal viruses, primarily anelloviruses, increased gradually, with the highest abundance and variability detected at D + 100. Viruses with clinical importance for HSCT, including CMV, adenovirus and EBV, were confirmed and characterized at the molecular level, showing generally high cycle threshold values. Our findings demonstrate a rise in anellovirus abundance following allogeneic HSCT, with the highest levels observed at D + 100. Notably, D + 30 was identified as a critical time point for the reactivation of clinically significant viruses. This study underscores the potential of metagenomics in the identification of clinically relevant viruses and highlights the importance of monitoring latent viruses in immunocompromised populations, including allogeneic HSCT patients.

Indexed as

commensal viruseshematopoietic stem cell transplantationHSCTinfectiontorque teno virusTTVviral metagenomics

Identifiers

PMID39770761
PMCPMC11677183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.